Trial Profile

A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Apr 2025 Planned End Date changed from 1 Mar 2025 to 30 Nov 2026.
27 Apr 2025 Planned primary completion date changed from 1 Dec 2024 to 30 Jun 2026.
17 Oct 2024 According to an Alkeus Pharmaceuticals Media Release, Positive data from Study will be presented at the 128th annual meeting of the American Academy of Ophthalmology (AAO) being held in Chicago October 18-21, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com